Evaxion A Revenue Growth Rates (EVAX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Evaxion A  (NASDAQ: EVAX)
 

EVAX's Revenue Growth by Quarter and Year

Evaxion A's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EVAX Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 7.53
3rd Quarter September 0.00
2nd Quarter June 0.04
1st Quarter March 0.00
FY 7.57





EVAX Revenue fourth quarter 2025 Y/Y Growth Comment
Evaxion A reported Revenue surge of 125.39% year on year in the fourth quarter 2025, to $ 7.53 millions, this is lower than Evaxion A's recent average Revenue surge of 2302.97%.

Looking into fourth quarter 2025 results within Biotechnology & Pharmaceuticals industry 9 other companies have achieved higher Revenue growth. While Evaxion A' s Revenue doubling of 125.39% ranks overall at the positon no. 99 in the fourth quarter 2025.


EVAX Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 125.39 % 4671.43 % - -
3rd Quarter September - - - -
2nd Quarter June -73.33 % - - -
1st Quarter March - - - -
FY   116.85 % 4885.71 % - -

Financial Statements
Evaxion A's fourth quarter 2025 Revenue $ 7.53 millions EVAX's Income Statement
Evaxion A's fourth quarter 2024 Revenue $ 3.34 millions Quarterly EVAX's Income Statement


EVAX Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   116.85 % 4885.71 % - -


Back to EVAX Growth rate Comparisons >> Back to EVAX Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #10
Healthcare Sector #33
Overall #99

Revenue Y/Y Growth Statistics
High Average Low
4480.82 % 2302.97 % 125.12 %
 
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #10
Healthcare Sector #33
Overall #99
Revenue Y/Y Growth Statistics
High Average Low
4480.82 % 2302.97 % 125.12 %
 

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Evaxion A's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


EVAX's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


EVAX's IV. Quarter Q/Q Revenue Comment


Evaxion A's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 7.53 $ 3.34 $ 0.07 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 125.12 % 4480.82 % - - -
Year on Year Revenue Growth Overall Ranking # 12 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 125.12 % 4480.82 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 12 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2025 period, Evaxion A's cumulative twelve months Revenue were $ 8 millions, company would post below average annual Revenue growth of 4480.82% year on year, if the fiscal year would end at Dec 31 2025.
A slow-down in the Evaxion A's Revenue growth from the 0% growth in Dec 31 2024. Despite that, Evaxion A showed the highest Revenue growth, among it's peers in Biotechnology & Pharmaceuticals industry.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 12.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 1
Healthcare Sector # 3
Overall # 12

Revenue TTM Y/Y Growth Statistics
High Average Low
4480.82 %
 2302.97 %
125.12 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 3
S&P 500 # 12
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2025 period, Evaxion A's cumulative twelve months Revenue were $ 8 millions, company would post below average annual Revenue growth of 125.12% year on year, if the fiscal year would end at Dec 31 2025.
A slow-down in the Evaxion A's Revenue growth from the 0% growth in Dec 31 2024. Despite that, Evaxion A showed the highest Revenue growth, among it's peers in Biotechnology & Pharmaceuticals industry.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 12.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 1
Healthcare Sector # 3
Overall # 12

Revenue TTM Y/Y Growth Statistics
High Average Low
4480.82 %
2302.97 %
125.12 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 3
S&P 500 # 12




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EVAX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Madrigal Pharmaceuticals Inc 210.77%$ 210.766 millions
Biocryst Pharmaceuticals Inc 209.09%$ 209.087 millions
Prenetics Global Limited201.94%$ 201.941 millions
Prokidney Corp 196.05%$ 196.053 millions
Mesoblast Limited191.39%$ 191.393 millions
Northwest Biotherapeutics Inc190.91%$ 190.909 millions
Zevra Therapeutics Inc 183.36%$ 183.360 millions
Spero Therapeutics Inc 174.51%$ 174.508 millions
Taysha Gene Therapies Inc 171.27%$ 171.266 millions
Compugen Ltd161.14%$ 161.140 millions
Nyxoah Sa156.29%$ 156.287 millions
Nuo Therapeutics Inc 153.57%$ 153.570 millions
Anaptysbio Inc 151.08%$ 151.082 millions
Theravance Biopharma inc 144.70%$ 144.700 millions
Voyager Therapeutics Inc 144.28%$ 144.282 millions
Esperion Therapeutics Inc 143.73%$ 143.725 millions
Foxo Technologies Inc 141.54%$ 141.542 millions
Volitionrx Limited133.25%$ 133.247 millions
Lineage Cell Therapeutics Inc 130.40%$ 130.404 millions
Tarsus Pharmaceuticals Inc 128.39%$ 128.388 millions
Evaxion A125.12%$ 125.120 millions
Cybin Inc 123.74%$ 123.742 millions
Elite Pharmaceuticals Inc 119.23%$ 119.225 millions
Pavmed Inc 116.67%$ 116.667 millions
Macrogenics Inc 113.03%$ 113.032 millions
C4 Therapeutics Inc 112.79%$ 112.787 millions
Vyne Therapeutics Inc 111.90%$ 111.905 millions
Tonix Pharmaceuticals Holding Corp 108.75%$ 108.753 millions
Phathom Pharmaceuticals Inc 94.12%$ 94.121 millions
Tenon Medical Inc 92.34%$ 92.338 millions


About Evaxion A Revenue Growth Rates (EVAX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Evaxion A s (CIK 1828253).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001171843-26-001346
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Evaxion A s’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.